Broadcast Date: 
  • Time: 

Lentiviral vectors are increasingly popular as gene delivery tools for cell and gene therapies. Their value has been demonstrated within CAR-T and TCR therapies for blood malignancies that don’t respond to current treatment, and research aims to exploit Lentiviral vectors for solid tumors. However, achieving high and scalable yields of Lentiviral vectors remains challenging. These challenges create an industry bottleneck and contribute to the high cost and low accessibility of novel treatments for patients.

In this GEN webinar, our expert panelists will discuss how they aim to develop technologies to improve Lentiviral vector yields and scalability. Specifically, we will hear about the challenges involved with the large-scale manufacture of Lentiviral vectors and how OXGENE’s LentiVEX™ plasmids are designed for high vector yields and can be used within transient manufacturing platforms. Our panelists will also describe the successful development of a transfection-free producer cell line, utilizing the same four plasmid set and HEK293 suspension host cell line as the transient system for ease of transition, Finally, the role of stable cell lines in the future of Lentiviral vector production will be discussed and how they are enabling greater efficiencies in the production of novel therapies and greater patient access to treatments.


A live Q&A followed the presentation, offering a chance to pose questions to our expert panelists.

Qing Wang
Qing Wang, PhD
Scientist, Viral Vector Process and Technology
WuXi Advanced Therapies
Matthew Tridgett
Matthew Tridgett, PhD
Senior Scientist, Viral Cell Line Development

Wuxi logo